Chronic myeloid leukemia (CML) epitomises successful targeted therapy with 90% patients in chronic phase treated with tyrosine kinase inhibitors (TKIs) attaining remission. This success eludes 80% patients in advanced phase of blast crisis (BC) who are resistant to TKIs and have poor survival. Since continued administration of TKIs is necessary to sustain remission, patients are on TKIs for a longer period with higher probability of resistance, relapse and progression to BC. This study is aimed at profiling of chromosomal aberrations, in CD34+ cells from CML at distinct phases, both sensitive and resistant to TKIs. The identified molecular alterations are expected to harbour potential therapeutic targets for BC and will help in understanding the molecular mechanism of TKI resistance and disease progression in CML.